ANI Pharmaceuticals | ANIP - Operating Expenses

Stock Price
77.77
Daily Change
-0.33 -0.42%
Monthly
-9.06%
Yearly
34.23%
Q1 Forecast
75.36

ANI Pharmaceuticals reported $505.82M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
ANI Pharmaceuticals USD 505.82M 309.62M Sep/2025
Assertio Holdings USD 105.8M 12.5M Sep/2025
Aurora Cannabis CAD 146.03M 27.79M Sep/2025
Canopy Growth CAD 80.99M 8.64M Sep/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Heron Therapeutics USD 38.47M 4M Sep/2024
Hikma Pharmaceutical USD 642M 663M Jun/2025
Knight Therapeutics CAD 89.06M 2.02M Sep/2024
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Novartis USD 9.77B 401M Sep/2025
Omeros USD 59.16M 20.13M Jun/2024
Perrigo USD 949.9M 50.8M Sep/2025
Sun Pharmaceuticals INR 111.11B 6.97B Sep/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025